This inventor holds 229 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Formulations (CPC class 424263). Top assignees: Merck + Co., Inc., Pharmacopeia Drug Discovery, Inc., Schering Corporation. Active years: 1976-2023.
Inventors with similar research interests:
Location History:
- Lansale, PA (US) (1977)
- Lansdale, PA (US) (1976 - 1985)
- Gwyneed Valley, PA (US) (1983 - 1993)
- Chelmsford, MA (US) (1994)
- Rahway, NJ (US) (1997)
- Gwyned Valley, PA (US) (1997)
- Houston, TX (US) (2010)
- Gwynedd, PA (US) (2007 - 2014)
- Gwynedd Valley, PA (US) (1982 - 2023)
Company Filing History:
167 out of 4,770 
19 out of 52 
18 out of 1,829 
Years Active: 1976-2023
Areas of Expertise:
Title: John J Baldwin: A Pioneer in Pharmaceutical Formulations and Ophthalmic Compositions
Introduction:
In the realm of pharmaceutical innovations, certain inventors make significant contributions that shape the industry. John J Baldwin, hailing from Gwynedd Valley, PA (US), is one such pioneering creator. With an impressive record of 223 patents, Baldwin has revolutionized the field with his groundbreaking work. This article will delve into some of his remarkable inventions, highlight his career accomplishments, and explore his collaborations with notable colleagues.
Latest Patents:
Among John J Baldwin's recent patents, two stand out for their potential to transform medical treatments. The first involves his formulation of pharmaceutical compositions that form gel in situ. These aqueous formulations, consisting of an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a pH regulator, and water, create a gel-like substance upon application, effectively treating infectious diseases of the skin or body cavities.
In his second recent patent, Baldwin focuses on slow-releasing ophthalmic compositions comprising povidone iodine. These novel compositions, developed in his quest to combat acute eye infections caused by various agents, offer prolonged treatment and even preventive measures. The ophthalmic compositions contain povidone iodine, an osmotic pressure regulator, suspending agent, and EDTA-Na, forming microsphere particles using PVP-I and sodium alginate.
Career Highlights:
John J Baldwin's exemplary career spans across prominent pharmaceutical companies, where he has made remarkable advancements. Baldwin's journey began at Merck & Company, Inc., a leading pharmaceutical giant, where he honed his skills and pioneered transformative pharmaceutical technologies. His innovative spirit and dedication to scientific excellence led him to explore new opportunities with Pharmacopeia Drug Discovery, Inc., where he continued to push boundaries and make groundbreaking contributions to the industry.
Collaborations:
Throughout his career, Baldwin has collaborated with esteemed colleagues who share his passion for innovation. Notable among his collaborators are Gerald S Ponticello and David A Claremon. These synergistic collaborations have resulted in enhanced research and development efforts, producing cutting-edge solutions to complex medical challenges.
Conclusion:
John J Baldwin's name reverberates through the halls of pharmaceutical innovation, as his groundbreaking patents continue to redefine the industry. His expertise in developing pharmaceutical formulations that form gel in situ and slow-releasing ophthalmic compositions represents a significant breakthrough in the treatment and prevention of infections. Baldwin's contributions, both independently and through collaborations, have undoubtedly paved the way for new therapies and improved patient outcomes. As the pharmaceutical field evolves, we eagerly anticipate the next wave of innovations from this exceptional mind.